TG Therapeutics used the AAN 2026 stage to advance the positioning of BRIUMVI in relapsing multiple sclerosis, presenting new Phase 4 real-world evidence from ENABLE and updated data from ENHANCE on a modified intravenous dosing regimen. While the announcements are conference abstracts rather than registrational milestones, they target exactly where the battle for share in the anti-CD20 class is being fought: post-marketing performance and operational simplicity.
The strategic signal is clear. In a market dominated by Roche’s infusion incumbent and Novartis’s at-home subcutaneous option, TG is leaning into two levers it can control—real-world outcomes and infusion logistics. The question for commercial and medical leaders is whether credible RWE plus dose- and infusion-optimization can tip choice at the point of care, loosen payer guardrails, and expand BRIUMVI’s footprint across integrated delivery networks and community infusion sites before the next wave of competitors arrives.
Why this matters now is as much about system constraints as it is about efficacy. Payers remain under budget pressure and continue to rationalize MS formularies toward therapies that deliver strong relapse control with predictable total cost of care. HCPs and health systems are triaging chair time, staffing, and site-of-care shifts that reward faster infusions and fewer adverse events. Patients continue to prioritize convenience and tolerability alongside disease control. ENABLE’s real-world readout helps answer lingering questions around persistence, infection signals, discontinuation, and MRI activity outside controlled trials, the very endpoints payers and guideline committees increasingly scrutinize. ENHANCE’s dosing insights point to practical gains—shorter chair time, streamlined premedication, and potentially improved infusion-center throughput—that translate directly into operational value. If TG can validate a materially shorter, well-tolerated maintenance experience at scale, it creates a concrete talking point for access negotiations and IDN pathways.
The move also fits a broader industry playbook. With most MS DMTs approved on head-to-heads versus teriflunomide or historical controls, post-approval RWE has become the de facto arena for differentiation. Manufacturers are investing in pragmatic registries, dose-timing studies, and infusion workflow data to support value dossiers, close evidence gaps on subpopulations, and build narratives around health resource utilization. This is particularly relevant for anti-CD20s, where real-world immunosuppression management, vaccine response considerations, and infection monitoring drive payer and provider confidence. At the same time, the competitive horizon is shifting. BTK inhibitors are pressing toward late-stage readouts that could challenge the class on convenience and brain-penetrant mechanisms, while biosimilar pressure on adjacent therapies will sharpen payer demands for demonstrable, practice-level advantages.
For Commercial teams, the path forward is executional detail: hard contracting tied to site-of-care economics, network expansion with specialty infusions, and patient support that reduces administrative friction. For Medical Affairs, the mandate is depth over headlines—robust ENABLE analyses that map to real-world drivers of treatment success, transparent safety context, and education that standardizes modified dosing protocols across diverse practice settings. Competitors will counter with their own RWE and convenience narratives, so speed and credibility of evidence generation will be decisive.
The next inflection to watch is whether these data catalyze tangible shifts—formulary positioning upgrades, pathway inclusion within major IDNs, or guideline language that acknowledges dosing and infusion workflow advantages. If TG converts conference momentum into policy and practice change in the next 12 months, BRIUMVI could become the infusion-of-choice in RMS just as new modalities test the class—and the market resets its definition of value.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
